Reduction of perioperative rebleeding in aneurysmal subarachnoid hemorrhage with combination therapy of hemocoagulase and antifibrinolytics: A multicenter retrospective study

The preprint operates within the dominant paradigm of evidence-based medicine, specifically focusing on the established understanding of aneurysmal subarachnoid hemorrhage (aSAH) and its treatment. It investigates the efficacy of existing hemostatic agents, namely hemocoagulase and antifibrinolytics, in preventing rebleeding after aSAH interventions. This aligns with the current paradigm's focus on pharmacological interventions and quantifiable outcomes.

The preprint is classified as Normal Science due to its adherence to the established methodologies and assumptions of the current paradigm. It conducts a retrospective analysis of patient data to assess the efficacy of standard treatments. The research aims to refine existing treatment strategies within the accepted paradigm, rather than challenging or proposing a new paradigm. The study explores the combination of hemocoagulase and antifibrinolytics, an area where current evidence is lacking, but this exploration still falls within the existing paradigm of pharmacological intervention for aSAH. It seeks to optimize current practice by investigating the potential benefits of combined therapy, which represents puzzle-solving activity characteristic of normal science. The study does not introduce any radically new concepts or challenge the fundamental understanding of aSAH or its management. Instead, it contributes to the existing body of knowledge by providing further data on the efficacy of different treatment approaches.